Scarica l'app Stockscreener
2.6339
1.00%
0.0239
Precedente Chiudi:
$2.61
Aprire:
$2.65
Volume 24 ore:
78,897
Relative Volume:
0.11
Capitalizzazione di mercato:
$167.81M
Reddito:
-
Utile/perdita netta:
$-36.95M
Rapporto P/E:
-3.1356
EPS:
-0.84
Flusso di cassa netto:
$-33.46M
1 W Prestazione:
-13.00%
1M Prestazione:
-21.07%
6M Prestazione:
-63.39%
1 anno Prestazione:
-69.68%
Intervallo 1D:
$2.61
$2.70
Intervallo di 1 settimana:
$2.5417
$3.05
Portata 52W:
$2.5417
$11.20
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Nome
Larimar Therapeutics Inc
Settore
Industria
Telefono
844-511-9056
Indirizzo
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Confronta LRMR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
2.635 | 167.81M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
511.27 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
671.49 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
603.30 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.81 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.80 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Iniziato | Truist | Buy |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-10-03 | Iniziato | Wedbush | Outperform |
| 2024-10-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-03 | Iniziato | Leerink Partners | Outperform |
| 2023-11-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-19 | Iniziato | Guggenheim | Buy |
| 2022-02-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-02-01 | Iniziato | William Blair | Outperform |
Mostra tutto
Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie
Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MSN
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire
Will Larimar's Rare Disease Pipeline Updates Move the Needle? Key Investor Conference Coming - StockTitan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Financial Metrics Exploration: Understanding Larimar Therapeutics Inc (LRMR) Through Ratios - The Dwinnex
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Boosted by SG Americas Securities LLC - Defense World
Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St
BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com
Insider’s View: Deciphering Larimar Therapeutics Inc (LRMR)’s Financial Health Through Ratios - The Dwinnex
Larimar Therapeutics Inc (LRMR)’s stock chart: A technical perspective - US Post News
Analysts Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.13 - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated at Truist Financial - MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Bought by JPMorgan Chase & Co. - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Buy” from Analysts - Defense World
Truist Financial Initiates Coverage on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar started at buy by Truist on Friedreich's ataxia drug - MSN
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target -January 29, 2025 at 06:37 am EST - Marketscreener.com
This MicroStrategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Larimar Therapeutics awards key executives performance-based stock By Investing.com - Investing.com Australia
Larimar Therapeutics Aligns Executive Incentives with Milestones - MSN
Larimar Therapeutics awards key executives performance-based stock - MSN
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment - MSN
JMP Securities maintains $21 target on Larimar Therapeutics stock - MSN
Larimar Therapeutics (NASDAQ:LRMR) Earns “Buy” Rating from HC Wainwright - Defense World
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia - MSN
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Australia
Assenagon Asset Management S.A. Sells 6,488 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics’ SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Nigeria
Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat
Larimar Therapeutics, Inc. Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Marketscreener.com
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - Business Upturn
Larimar Therapeutics Announces Dosing of Adolescents in - GlobeNewswire
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN
Barclays PLC Buys 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.43 - MarketBeat
Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock - Yahoo Finance
Geode Capital Management LLC Decreases Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Geode Capital Management LLC Has $5.90 Million Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics Inc Azioni (LRMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.28%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):